Ana Sayfa › Multiple Miyelom › North Carolina › Durham
Durham, NC içinde Multiple Miyelom klinik çalışmaları
Multiple Miyelom için 37 çalışma, Durham ve çevresindeki (yaklaşık 30 mil mesafedeki) merkezlerde katılımcı arıyor. Kimlerin katılabileceğini ve çalışma ekibine nasıl ulaşılacağını görmek için bir çalışmayı açın.
Resmi çalışma metni (İngilizce)
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
Katılımcı aranıyorEvre 3
- Research Site, Chapel Hill · 10 mil uzakta
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
Katılımcı aranıyorEvre 3
- Duke University Medical Center, Durham
A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events
Katılımcı aranıyorEvre 2
- Duke University Medical Center, Durham
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
Katılımcı aranıyorEvre 3
- Durham VAMC, Durham
- University of North Carolina, Chapel Hill · 10 mil uzakta
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
Katılımcı aranıyorEvre 3
- Durham VAMC, Durham
A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
Katılımcı aranıyorEvre 2/3
- University of North Carolina at Chapel Hill /ID# 277708, Chapel Hill · 10 mil uzakta
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Katılımcı aranıyorEvre 2
- Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mil uzakta
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
Katılımcı aranıyorEvre 3
- Duke University, Durham
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
Katılımcı aranıyorEvre 2
- University of North Carolina Medical Center, Chapel Hill · 10 mil uzakta
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
Katılımcı aranıyorEvre 1/2
- University of North Carolina at Chapel Hill /ID# 272454, Chapel Hill · 10 mil uzakta
HCMT/MM2401: Ph2 Study of Selinexor + Bispecific Antibody for RRMM
Katılımcı aranıyorEvre 2
- Duke University Health System, Durham
Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
Katılımcı aranıyorEvre 1
- University of North Carolina Hospitals at Hillsborough, Hillsborough · 13 mil uzakta
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
Katılımcı aranıyorEvre 1/2
- GSK Investigational Site, Chapel Hill · 10 mil uzakta
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
Katılımcı aranıyorEvre 1
- Duke University Hospital, Durham
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
Katılımcı aranıyorEvre 1/2
- Research Site, Durham
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
Katılımcı aranıyorEvre 3
- Research Site, Durham
- Research Site, Chapel Hill · 10 mil uzakta
DISCOVERY: Evaluating a Decision Support Tool for Adults Seen in Hematology/Oncology Clinics
Katılımcı aranıyor
- Lineberger Comphrehensive Cancer Center at University of North Carolina, Chapel Hill · 10 mil uzakta
A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
Katılımcı aranıyorEvre 1
- Duke Cancer Center, Durham
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
Katılımcı aranıyorEvre 2
- UNC Hospitals Adult Oncology Clinics, Chapel Hill · 10 mil uzakta
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
Katılımcı aranıyorEvre 1/2
- University of North Carolina at Chapel Hill /ID# 274667, Chapel Hill · 10 mil uzakta
Selinexor and Backbone Treatments of Multiple Myeloma Patients
Katılımcı aranıyorEvre 1/2
- Duke Institute of Cancer/ Duke University, Durham
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
Katılımcı aranıyorEvre 1
- University of North Carolina /ID# 251203, Chapel Hill · 10 mil uzakta
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
Katılımcı aranıyorEvre 1
- University of North Carolina at Chapel Hill, Chapel Hill · 10 mil uzakta
A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)
Katılımcı aranıyorEvre 2
- University of North Carolina (Data Collection Only), Chapel Hill · 10 mil uzakta
Registry of Older Patients With Cancer
Katılımcı aranıyorGözlemsel çalışma
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill · 10 mil uzakta
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
Katılımcı aranıyorEvre 3
- Duke University, Durham
Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma
Katılımcı aranıyorEvre 2
- University of North Carolina, Chapel Hill · 10 mil uzakta
Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
Katılımcı aranıyorEvre 2
- Duke Comprehensive Cancer Center, Durham
- University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mil uzakta
Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma
Katılımcı aranıyorEvre 1
- University of North Carolina Hospitals at Hillsborough, Chapel Hill · 10 mil uzakta
A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment
Katılımcı aranıyorEvre 1/2
- Duke University Health System (DUHS), Durham
Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma
Katılımcı aranıyorEvre 1
- University Of North Carolina Health Care - Hillsborough Campus /ID# 278230, Hillsborough · 13 mil uzakta
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
Katılımcı aranıyorEvre 1
- University of North Carolina, Chapel Hill · 10 mil uzakta
Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)
Katılımcı aranıyorEvre 1
- University of North Carolina, Chapel Hill · 10 mil uzakta
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Katılımcı aranıyorEvre 1/2
- Duke University, Durham
- UNC Hospital, Chapel Hill · 10 mil uzakta
Registry for Adults With Plasma Cell Disorders (PCD's)
Katılımcı aranıyorGözlemsel çalışma
- North Carolina Cancer Hospital, Chapel Hill · 10 mil uzakta
Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
Katılımcı aranıyorGözlemsel çalışma
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill · 10 mil uzakta
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
Katılımcı aranıyorEvre 1
- Duke University Health System (DUHS), Durham
Diğer şehirlerde Multiple Miyelom çalışmaları
- New York City, NY60 çalışma
- Boston, MA42 çalışma
- Atlanta, GA41 çalışma
- Houston, TX38 çalışma
- Nashville, TN32 çalışma
- Denver, CO27 çalışma
- Rochester, MN24 çalışma
- St. Louis, MO24 çalışma
- Columbus, OH24 çalışma
- Baldwin Park, CA23 çalışma
- Chicago, IL22 çalışma
- Seattle, WA22 çalışma
Durham içinde diğer çalışmalar
- Meme Kanseri63 çalışma
- Kanser (tüm türler)58 çalışma
- Küçük Hücreli Olmayan Akciğer Kanseri39 çalışma
- Metastatik Kanser33 çalışma
- Akut Miyeloid Lösemi33 çalışma
- Akciğer Kanseri32 çalışma
- Prostat Kanseri32 çalışma
- Kolorektal Kanser28 çalışma
- Kronik Lenfositik Lösemi27 çalışma
- Yumurtalık Kanseri27 çalışma
- Kalp Yetmezliği26 çalışma
- Pankreas Kanseri24 çalışma
ClinicalTrials.gov'dan alınmıştır, veri tarihi: 5 Eki 2026. Her çalışma kendi uygunluk kriterlerini belirler; katılım kararı çalışma ekibine aittir.